详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

GAL-9: A predictive biomarker negatively regulating immune response in glioma patients.

文献详情

资源类型：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. [2]Capital Medical University, Beijing 100069, China. [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.

出处：

DOI：

ISSN：

摘要：

Glioma was the most frequent primary brain tumor. Immunotherapy is one of the most promising therapeutic approaches for gliomas. TIM-3 can induce the malignancy of gliomas. The function of GAL-9, as one of the ligands of TIM-3, in glioma has still remained elusive. In this study, we attempted to characterize the expression of GAL-9 in glioma patients. In the present study, 1292 glioma patients from GSE 16011 array set, Chinese Glioma Genome Atlas (CGGA), and The Cancer Genome Atlas (TCGA) datasets were enrolled. The Kaplan-Meier analysis was undertaken to explore the prognostic value of GAL-9. GraphPad software and R language were used for statistical analysis. Our research indicated that expression of GAL-9 was highly correlated with major clinical and molecular features. Patients with high expression of GAL-9 were more susceptible to have malignant tumors. Gene Ontology (GO) analysis revealed that expression of GAL-9 was closely associated with function of immune response in glioma. Clinically, the results of Kaplan-Meier analysis showed that expression of GAL-9 was negatively associated with OS in all grade glioma and HGGs. High expression of GAL-9 was an independent indicator of poor prognosis. Our results highlighted the pivotal role of GAL-9 in regulation of glioma's immune suppressive features, and indicated that GAL-9 was a promising target for cancer immunotherapy, and may result in developing further therapeutic strategies. Copyright © 2019. Published by Elsevier Inc.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区外科 4 区临床神经病学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区临床神经病学 4 区外科

JCR分区：

出版当年[2017]版：

Q2 SURGERY Q3 CLINICAL NEUROLOGY

最新[2023]版：

Q2 SURGERY Q3 CLINICAL NEUROLOGY

影响因子： 1.9 最新[2023版] 2 最新五年平均 1.924 出版当年[2017版] 2.326 出版当年五年平均 2.592 出版前一年[2016版] 1.723 出版后一年[2018版]

第一作者：

第一作者机构： [1]Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

共同第一作者：

通讯作者：

通讯机构： [3]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China. [*1]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

推荐引用方式(GB/T 7714)：

APA：

MLA：